14 results
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
(%) White Asian Black/African American Not reported 0 39 (100.0) 0 0 5 (9.4) 48 (90.6) 0 0 4 (7.5) 46 (86.8) 1 (1.9) 2 (3.8) Mean BMI, kg/m2 (SD) 21.4
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
5 Jan 22
Current report (foreign)
5:24pm
%) Asian 9 (16%) 17 (30%) 12 (21%) 38 (22%) 14 (25%) 52 (23%) Black/African American 7 (12%) 8 (14%) 10 (18%) 25 (15%) 6 (11%) 31 (14%) † Not Hispanic/Latino
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
5 Jun 23
Current report (foreign)
4:28pm
( 35.9) 20 (37.7) 20 (37.7) Race, n (%) White Asian Black/African American Not reported 0 39 (100.0) 0 0 5 (9.4) 48 (90.6) 0 0 4 (7.5) 46 (86.8) 1 (1.9
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
the Binomial option-pricing model to determine the fair value of options as of the grant date. Separately, the Group used the Black-Scholes option
6-K
CNTB
Connect Biopharma Holdings Ltd
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
model to determine the fair value of options as of the grant date. Separately, the Group used the Black-Scholes option-pricing model to determine
424B4
oiv5jd77
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1
6u6us29m
26 Feb 21
Registration statement (foreign)
4:56pm
DRS/A
rrkk2li7ctuze69o55
26 Jan 21
Draft registration statement (amended)
12:00am
F-1/A
d3owrnhh6 0w
18 Mar 21
Registration statement (foreign) (amended)
6:15am
F-1/A
i7hay shb0
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
DRS
sxoyupb8ugvclcdx
17 Dec 20
Draft registration statement
12:00am
20-F
dqahlp6sfzlvn
31 Mar 22
Annual report (foreign)
4:33pm
- Prev
- 1
- Next